[go: up one dir, main page]

MX2010008942A - Paramyxovirus eficaz como antitumoral. - Google Patents

Paramyxovirus eficaz como antitumoral.

Info

Publication number
MX2010008942A
MX2010008942A MX2010008942A MX2010008942A MX2010008942A MX 2010008942 A MX2010008942 A MX 2010008942A MX 2010008942 A MX2010008942 A MX 2010008942A MX 2010008942 A MX2010008942 A MX 2010008942A MX 2010008942 A MX2010008942 A MX 2010008942A
Authority
MX
Mexico
Prior art keywords
virus
paramyxovirus
tumour
human normal
genes
Prior art date
Application number
MX2010008942A
Other languages
English (en)
Inventor
Rudolf Beier
Florian Puehler
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MX2010008942A publication Critical patent/MX2010008942A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen paramyxovirus del grupo APMV3, APMV4, APMV5, APMV6, APMV7, APMV8, APMV9, virus Mapuera y virus Fer-de-Lance, los cuales pueden ser usados para la producción de un medicamento para el tratamiento de tumores. El virus tiene una selectividad para matar células tumorales humanas pero no para matar células diferenciadas normales humanas o en proliferación normal humanas con la misma dosis. Por medio de ingeniería genética, el virus se puede modificar de modo tal que se agreguen o reemplacen uno o más genes por los genes homólogos de un paramyxovirus relacionado. Por ese método, la actividad antitumoral del virus quimérico resultante se potencia en comparación con el virus parental.
MX2010008942A 2008-02-14 2009-02-12 Paramyxovirus eficaz como antitumoral. MX2010008942A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08075121 2008-02-14
US2965008P 2008-02-19 2008-02-19
PCT/EP2009/051659 WO2009101149A2 (en) 2008-02-14 2009-02-12 Anti-tumour effective paramyxovirus

Publications (1)

Publication Number Publication Date
MX2010008942A true MX2010008942A (es) 2010-09-07

Family

ID=40955326

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008942A MX2010008942A (es) 2008-02-14 2009-02-12 Paramyxovirus eficaz como antitumoral.

Country Status (17)

Country Link
US (1) US20090208495A1 (es)
EP (1) EP2252307A2 (es)
JP (1) JP2011512344A (es)
KR (1) KR20100122482A (es)
CN (1) CN101945660A (es)
AU (1) AU2009214066A1 (es)
BR (1) BRPI0908365A2 (es)
CA (1) CA2715136A1 (es)
CO (1) CO6290694A2 (es)
CR (1) CR11631A (es)
DO (1) DOP2010000251A (es)
EA (1) EA201001266A1 (es)
EC (1) ECSP10010401A (es)
IL (1) IL206860A0 (es)
MX (1) MX2010008942A (es)
WO (1) WO2009101149A2 (es)
ZA (1) ZA201006561B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2592544C2 (ru) * 2009-08-21 2016-07-20 Мериал, Инк. Способ получения рекомбинантного вирусного вектора apmv-8
GB0915515D0 (en) * 2009-09-04 2009-10-07 Ucl Business Plc Treatment of vasculoproliferative conditions
US20130084264A1 (en) * 2010-06-10 2013-04-04 Carla Christina Schrier Anti-tumor composition
PT2806891T (pt) * 2012-01-24 2019-07-01 Univ Georgia Vacinas baseadas no vírus parainfluenza 5
EA039404B1 (ru) 2013-09-03 2022-01-24 Медиммун Лимитед Аттенуированный вирус ньюкаслской болезни (ndv) штамма 73т для лечения неоплазии, способ селективного цитолиза опухолевых клеток и способ индуцирования регресса опухоли с его использованием
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2020014591A1 (en) * 2018-07-13 2020-01-16 Icahn School Of Medicine At Mount Sinai Apmv and uses thereof for the treatment of cancer
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
CN115089591B (zh) * 2022-05-21 2024-04-12 复旦大学 布立尼布在制备抑制肠道病毒71型嗜神经性病毒药物中的应用
CN116970650B (zh) * 2023-09-22 2023-12-08 深圳华大生命科学研究院 一种包膜蛋白组合、含其的靶向病毒载体及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2370187C (en) * 1999-04-15 2011-08-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
EP1217891B1 (en) * 1999-09-24 2009-12-16 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
BRPI0517834A (pt) * 2004-11-12 2008-10-21 Bayer Schering Pharma Ag vìrus da doença de newcastle recombinante

Also Published As

Publication number Publication date
ECSP10010401A (es) 2010-09-30
CA2715136A1 (en) 2009-08-20
EP2252307A2 (en) 2010-11-24
CN101945660A (zh) 2011-01-12
IL206860A0 (en) 2010-12-30
WO2009101149A3 (en) 2009-11-05
JP2011512344A (ja) 2011-04-21
BRPI0908365A2 (pt) 2015-08-11
AU2009214066A1 (en) 2009-08-20
DOP2010000251A (es) 2010-08-31
US20090208495A1 (en) 2009-08-20
KR20100122482A (ko) 2010-11-22
ZA201006561B (en) 2012-02-29
EA201001266A1 (ru) 2011-04-29
CR11631A (es) 2010-10-05
CO6290694A2 (es) 2011-06-20
WO2009101149A2 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
MX2010008942A (es) Paramyxovirus eficaz como antitumoral.
PH12020550450A1 (en) Certain chemical entities, compositions and methods
BR112017017810A2 (pt) materiais e métodos para tratamento de hemoglobinopatias
MX2012010434A (es) Compuestos y composiciones novedosas para atacar a las celulas madre del cancer.
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
MX2012003770A (es) Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
MX365365B (es) Induccion de gen de trail de molécula pequeña en células normales y tumorales como una terapia anticáncer.
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
NZ603901A (en) Vectors and sequences for the treatment of diseases
MX2010003371A (es) Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
MY171561A (en) Conjugates for treating diseases caused by psma expressing cells
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2012001306A (es) Inhibicion de matastasis de tumor.
MX348024B (es) Compuestos de adamantilo.
BR112015010225A2 (pt) compostos tricíclicos e seus métodos de produção e utilização
MX2011008994A (es) Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
WO2013012771A3 (en) Clinical applications of a recombinant human endostatin adenovirus (e10a) injection
GB2528604A (en) Modulation of asymmetric proliferation

Legal Events

Date Code Title Description
FA Abandonment or withdrawal